Merrimack Pharmaceuticals Inc MACK:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/01/24 EDT
14.98quote price arrow up+0.24 (+1.63%)
Volume
304,765
52 week range
11.53 - 15.89
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close14.98
  • 52 Week High15.89
  • 52 Week High Date02/13/24
  • 52 Week Low11.53
  • 52 Week Low Date07/19/23

Key Stats

  • Market Cap217.686M
  • Shares Out14.53M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.44
  • YTD % Change11.71

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close14.98
  • 52 Week High15.89
  • 52 Week High Date02/13/24
  • 52 Week Low11.53
  • 52 Week Low Date07/19/23
  • Market Cap217.686M
  • Shares Out14.53M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.44
  • YTD % Change11.71

RATIOS/PROFITABILITY

  • EPS (TTM)-0.08
  • P/E (TTM)-181.36
  • Fwd P/E (NTM)-4.65
  • EBITDA (TTM)-2.176M
  • ROE (TTM)-6.22%
  • Revenue (TTM)-
  • Gross Margin (TTM)94.58%
  • Net Margin (TTM)-159.70%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date12/13/2019
  • Div Amount0.50
  • Split Date-
  • Split Factor-

Latest On Merrimack Pharmaceuticals Inc

 

Profile

MORE
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the...
Gary Crocker
Chairman of the Board, President, Treasurer
Address
One Broadway, 14Th Floor
Cambridge, MA
02142
United States

Top Peers

SYMBOLLASTCHG%CHG
GALT
Galectin Therapeutics Inc
3.50-0.01-0.28%
DSGN
Design Therapeutics Inc
3.62+0.10+2.84%
CRVO
CervoMed Inc
24.17-0.12-0.49%
OVID
Ovid Therapeutics Inc
3.06+0.01+0.33%
PRLD
Prelude Therapeutics Inc
3.73-0.04-1.06%